http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer Completes Acquisition of Anacor
-
Pfizer Declares 30-Cent Third-Quarter 2016 Dividend
-
Pfizer (PFE) Selects Oracle's (ORCL) Cloud Services for Clinical Data Management
-
Help Pfizer Change The Future Of Healthy Aging
-
Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts
-
Pfizer (PFE) Announces Publication of Final Phase 3 INO-VATE ALL Data; PFS Improvement Noted
-
Pfizer Announces Final Results from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
-
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
-
Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination
-
Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval
-
Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ®) Providing Clinicians With Additional Information For The Treatment Of Moderate to Severe RA
-
Pfizer (PFE) Announces Positive Top-Line XELJANZ Phase 3 Data in PsA
-
Pfizer Announces Positive Top-Line Results from Second Phase 3 Trial of Oral XELJANZ® (Tofacitinib Citrate) in Adults with Psoriatic Arthritis
-
ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma
-
ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma
-
Pfizer (PFE) Announces Positive Lorlatinib Phase 1/2 Data in NSCLC; Positive Response Noted
-
Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer
-
Pfizer (PFE) Announces Encouraging Safety Data from Utomilumab Combo Phase 1b in Adv. Solid Tumors
-
Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor
-
Pfizer Prices $5.0 Billion Debt Offering
-
CHAMPIX® (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP
-
Pfizer (PFE) Announces EMA Acceptance of TRUMENBA Marketing App
-
Pfizer Announces European Medicines Agency Acceptance for Review of Marketing Authorization Application for TRUMENBA® (Meningococcal Group B Vaccine)
-
On BizWireTV: Streaming Service Finds Television and Climate Change on the Radar
-
Hospira Launches LifeCare PCA® 7.0 Infusion System, First PCA Pump That Integrates with the Electronic Medical Record
-
Spark Therapeutics (ONCE), Pfizer (PFE) to Present Encouraging SPK-9001 Data at EHA Congress
-
Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression
-
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
-
Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
-
Pfizer (PFE) to Showcase Diverse and Growing Oncology Portfolio at ASCO
-
Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
-
Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA)
-
Pfizer (PFE) to Acquire Anacor Pharmaceuticals (ANAC) in $5.2B Deal
-
Pfizer to Acquire Anacor
-
Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative
-
WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases
-
Pfizer Hosts Annual Meeting of Shareholders
-
Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled
-
Pfizer (PFE) Announces Publication of Data from Largest Smoking Cessation Medicines Trial
-
CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet
-
Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)
-
On the Latest BizWireTV Cars Get Night Vision and Healthy Eating Made More Accessible
-
Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care
-
Pfizer (PFE) Receives EMA CHMP Approval for MDV Presentation of Prevenar 13
-
Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®
-
Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)
-
Pfizer Announces Termination of Proposed Combination with Allergan
-
Pfizer (PFE) Announces FDA Approval for INFLECTRA (Biosimilar Infliximab)
-
FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications
-
Pre-Open Stock Movers 04/05: (VRX) (MRVL) (ICPT) Higher; (PSUN) (AGN) (NATI) Lower (more...)

